The first new Alzheimer’s drug since 2003 approved by FDA.
The approval came despite the advisory committee’s near-unanimous vote against it. “The approval, however, will do little to quell criticisms from the swath of Alzheimer’s researchers, biostatisticians, and clinicians who have argued that Biogen cherry-picked data and failed to show convincing evidence that the drug can slow patients’ cognitive decline.” | learn more